Special Therapies · ViveCura Berlin

Ketamine-Assisted Therapy: Hope for Treatment-Resistant Mental Health Conditions

What the evidence supports, what it leaves open, and why the setting matters at least as much as the substance.

Imagine a medication that works in hours.

Not in six weeks. In hours.

A medication to which, in the aggregated real-world evidence, about 45 out of 100 people with treatment-resistant depression respond, with around 30 reaching remission. Response means the symptoms are cut in half. It does not mean the depression is gone. For a group in which two or more antidepressants did nothing, those are still remarkable numbers. In studies, suicidal thoughts were also reduced within hours.

And still many people have never seriously heard of it.

Many people hear the name ketamine and immediately think: party drug. Anesthetic. Risk of dependence. These questions are understandable, and they are important. This is where a misunderstanding often begins.

Between the operating theater and the party basement, there is a third space. A medical, therapeutic space. A space in which ketamine does not numb, but can open something. And exactly there lies the difference between a crash and a therapeutic process.

If you want to know directly whether this is relevant for you At the end of this article you will find a self-check and an overview of indications, contraindications, and side effects.

Specialty area at ViveCura: Ketamine-assisted therapy & integration

Ketamine therapy is one of my four focus areas, alongside Gut Reset, mold treatment, and heavy-metal detoxification. I do not offer this therapy out of theoretical interest. In my own life I have learned how large the difference between understanding and experiencing can be. That is exactly why I place so much weight on integration, on the work that comes after the session.

Current area Off-label, physician-supervised Integration in focus
My honest framing before you read on

Behavioral therapy and psychoanalysis are effective, well-studied treatments. For many people they are exactly the right thing.

What I additionally observe with a ketamine-assisted treatment is a different quality: it can be less about understanding and more about experiencing. Whether that turns into lasting change is not decided in the session, but in the work afterwards. I cannot promise that to anyone.

I am from Syria. And Germany was not home for a long time.

I am grateful for this country, I have to say that here, without qualification. Germany gave me safety when my homeland could no longer do so. It made it possible for me to study medicine, to build a practice, to live a good life despite all the difficulties. I do not forget that.

And still: at home is something I did not feel here for a long time. Safe, yes. Welcomed, yes. But that deep, quiet sense of “this is where I belong” was missing. For years. I kept thinking: maybe at some point I will leave. Maybe this is not permanently mine.

“Where is your home?” That question followed me. And no thought, no analysis, no conversation truly answered it.

The answer did come eventually. But not as a thought, and not at the end of an analysis. It came as an experience: physical, emotional, in images. I can still barely put it into words.

Home is not a place. Home is a feeling on the inside that I can cultivate, regardless of where I happen to be living.

After that, I no longer wanted to leave. Not because Germany had changed, but because I had changed. I stopped expecting an external place to give me what can only arise on the inside. I started experiencing my practice in Berlin as a deliberate choice, not as a temporary stop. I stayed. Not because I had to, but because I wanted to.

The second theme: knowing and changing are two different things.

I was in psychoanalysis. Intensively. It was good. I came to understand a lot about myself, my patterns, my relationship dynamics, the structures that kept repeating in my partnership at the time. I saw what was not working. I knew the causes. I understood my pattern, intellectually and completely.

And still nothing essential changed. Not really. The head knew. The rest of me did not.

I knew my pattern. I could name it, explain it, trace it back to childhood. And I lived it anyway. Knowing and changing are two completely different things.

What finally made the difference was something else. I no longer experienced my patterns as abstract concepts, I saw them. As inner images. As scenes that unfolded before me. I felt what these patterns had done to me, how they had come about, what they had once tried to protect. Not cognitively. Holistically. Feeling, understanding, and the will to change all at once, in a single moment.

That was what had been missing. Not more analysis. Not more knowing. The experience. The difference between reading a map and actually walking the path.

After that experience, change came more easily to me. Not because some substance had done it for me, but because for the first time I had truly felt what I had only ever thought. That is my own experience. It says nothing about what would happen for you.

Classical therapy

Understanding what is happening

Psychoanalysis and behavioral therapy create awareness, cognitive structures, new frames of meaning. You understand the pattern. You know how it came about. You can name it.

For many people this is exactly the path that works, and the evidence for it is good. Some additionally describe the wish to also feel what they have understood.

Ketamine-assisted therapy

Experiencing what is happening

Ketamine can open a state in which old patterns can not only be analyzed, but felt, through inner images, bodily sensations, emotional truths.

Some people describe that change feels easier afterwards. Whether that happens cannot be predicted, and nobody can take the work that follows off your hands.

1. What ketamine is, and what it is not

Ketamine was developed in the early 1960s as an anesthetic, and it is still used worldwide today. In emergency rooms, in operations, in pain therapy. In anesthesia it has a safety profile that differs from many other anesthetics: breathing is usually preserved, and circulation does not typically collapse. That does not make it free of side effects. Blood pressure and pulse can rise markedly, nausea is common, and with repeated use the liver and the bladder can be affected. This is why I examine beforehand and monitor throughout.

Then something fascinating was discovered. At a much lower dose, sub-anesthetic, it is called, ketamine can produce an almost opposite effect in depression, trauma, and chronic tension. Not numbing. But opening.

And exactly this discovery has turned the psychiatric research of the past twenty years on its head.

A pattern I hear more often

A pattern I hear more often is not sadness, but emptiness. People tell me they no longer feel depressed, they feel nothing at all. For many, that leaden indifference is the worst part of it. Whether a ketamine-assisted treatment can help with that can only be judged individually and after a thorough examination. Individual courses say nothing about it.

2. What happens in the brain, the neurobiology in plain language

Classical antidepressants work on the serotonin or norepinephrine system. That is important and effective. But it takes weeks, sometimes months. And it does not help everyone.

Ketamine takes a different route.

The NMDA receptor: the gateway to change

Ketamine blocks a specific receptor type in the brain: the NMDA receptor, a glutamate receptor. Glutamate is the most important excitatory messenger of the brain. Imagine NMDA receptors like locks that regulate the flow of information between nerve cells. In chronic depression, these locks could be stuck in an unhealthy pattern.

When ketamine blocks these receptors, according to the prevailing model something surprising happens at first: certain nerve cells are briefly freed from an inhibition. That can lead to a short-term rise in glutamate in other regions. This rise in glutamate could trigger a cascade that reaches into the architecture of the cell.

BDNF, mTOR, and synaptogenesis: what may be happening at the cellular level

Imagine BDNF, brain-derived neurotrophic factor, as the fertilizer of the brain. Chronic stress and depression reduce BDNF, the connections between nerve cells become weaker, thinner, fewer.

In animal models, ketamine rapidly triggers an increase in BDNF synthesis, presumably via the mTOR signaling pathway, a kind of cellular hub for growth signals. New synaptic connections form there as a result. In humans this cannot currently be measured directly. What we see is the clinical effect. The mechanism behind it is plausible, but not yet proven. Krystal and colleagues attribute this process, which neuroscientists call synaptogenesis, to both the rapid and the longer-lasting effects of ketamine in 2024 in Neuropsychopharmacology.

Mechanism review 2024

Krystal JH, Kavalali ET, and Monteggia LM published a comprehensive overview in 2024 in Neuropsychopharmacology. The core message: ketamine’s NMDA blockade inhibits eEF2 kinase, which lifts the suppression of BDNF translation. BDNF activates TrkB receptors, which leads to rapid synaptic plasticity. At the same time, AMPA receptor stimulation activates the mTOR pathway and promotes synaptogenesis. This model rests largely on preclinical data, and in humans the cascade has not been measured directly.

Krystal JH, Kavalali ET, Monteggia LM. Ketamine and rapid antidepressant action: new treatments and novel synaptic signaling mechanisms. Neuropsychopharmacology. 2024;49(1):41–50.

What does this mean for a person? In depression, the brain metaphorically receives fewer growth signals. Connections that stand for joy, hope, motivation may become weaker. Ketamine can set a counter-impulse in motion within hours. That distinguishes it from the classical antidepressants, which need weeks.

Reframe

Ketamine is not a happiness hormone. It is a growth impulse. It does not make you “happy.” For a defined period, it creates the neurobiological conditions under which change becomes possible. What happens in that window is decided in the therapeutic frame, in the integration, in the conversation afterwards. That is the difference between an experience and a therapeutic process.

3. How fast does ketamine work, and how long does it last?

This is perhaps the most fascinating part.

Classical antidepressants need six to eight weeks. Ketamine can begin to act within hours. In studies, the peak of the antidepressant effect lies between 24 and 72 hours after an infusion.

This is not mysticism. The explanation under discussion is synaptic growth processes that could begin immediately after the infusion.

Single infusion versus a series

A single infusion may keep working for up to seven days in many people. That is meaningful, but usually not enough for lasting change. Repeated infusions over two to three weeks can extend the effect, although the optimal number and frequency are still subjects of research.

Real-world meta-analysis

Alnefeesi and colleagues analyzed in 2022, in one of the most comprehensive reviews, 79 real-world studies with a total of 2,665 patients with treatment-resistant depression. The result: on average about 45% of patients showed a response (at least 50% symptom reduction), and about 30% reached remission. Importantly, the effect size was substantial (Hedges g = 1.44), and the effect did not fade with repeated treatment.

Alnefeesi Y et al. Real-world effectiveness of ketamine in treatment-resistant depression: a systematic review & meta-analysis. J Psychiatr Res. 2022;151:693–709.
An honest framing of the numbers

Individual controlled studies under optimal conditions report higher response rates. The aggregated real-world evidence shows lower numbers: about 45% response, 30% remission. That is still remarkable for a patient group that has not responded to anything else. But it is important to be honest with this: ketamine does not help everyone. And it does not simply make a depression go away. It can open a therapeutic space.

4. Treatment-resistant depression: when nothing else helps

I bet you know this feeling. Or you know someone who does.

Not sick enough to need a hospital, but not healthy enough to truly live. A life in gray. Medications that do nothing. Sessions that go in circles. That exhausted “I have already tried everything.”

Treatment-resistant depression is defined as the lack of improvement despite at least two adequate antidepressant treatments in the current depressive episode. This affects an estimated one in three people with severe depression.

Overview of overviews 2024

Rodolico and colleagues published in 2024 in Frontiers in Psychiatry an umbrella review of 26 systematic reviews and 44 randomized studies including more than 3,000 patients. Ketamine and its S-enantiomer esketamine appear effective and well tolerated in it. The authors are explicit at this point: the quality of the included reviews and original studies is poor, and the certainty of the evidence is correspondingly low. About long-term effects we know too little. This assessment therefore rests on a shaky evidence base.

Rodolico A et al. Efficacy and safety of ketamine and esketamine for unipolar and bipolar depression: an overview of systematic reviews with meta-analysis. Front Psychiatry. 2024;15:1325399.

What does that mean in practice? In treatment-resistant depression, ketamine can bring a noticeable relief within hours. It is not a magic remedy. Ketamine is currently one of the fastest-acting options we have in treatment-resistant depression. Other established procedures such as electroconvulsive therapy are comparably effective in head-to-head studies. What distinguishes ketamine is above all the speed, not automatically superiority.

And what about suicidality?

This is a particularly important point. Antidepressants usually need several weeks to reach their full effect. That is hard to endure, but it does not change the fact that they are effective and important. Please never stop an ongoing medication on your own, and not because of this article either. Discuss every change with the doctor who prescribed it.

In studies, ketamine was able to reduce suicidal thoughts within hours, sometimes after a single infusion. That can be clinically very significant. It does not replace emergency care.

If you are currently thinking about taking your own life

  • Please do not wait for an appointment, and do not stay alone with it.
  • In Germany: emergency number 112, around the clock
  • Medical on-call service 116 117
  • Telefonseelsorge, free and anonymous: 0800 111 0 111 or 0800 111 0 222, around the clock

5. Bipolar depression: when the dark phases will not lift

People with bipolar disorder know a particular dilemma: many medications help against mania, but barely against the deep depressive phases. And exactly in those phases lies the greatest risk.

Systematic review

Bahji, Zarate, and Vazquez published in 2021 in the International Journal of Neuropsychopharmacology a systematic review on ketamine in bipolar depression. They analyzed 6 studies with a total of 135 patients. Participants received ketamine infusions (0.5 mg/kg) in addition to a mood stabilizer. In most studies, the depressive phase improved rapidly. The risk of a manic switch was low, but present. The authors describe this as preliminary evidence that requires further research.

Bahji A, Zarate CA, Vazquez GH. Ketamine for bipolar depression: a systematic review. Int J Neuropsychopharmacol. 2021;24(7):535–541.
Important caveat: in bipolar disorder, ketamine is not a first-line treatment, and it should only be used in close psychiatric supervision and in combination with a mood stabilizer. The risk of a manic switch is low but real. Ketamine does not replace mood-stabilizing medication.

6. PTSD: when the trauma keeps living in the nervous system

Post-traumatic stress disorder arises after extreme experiences. Violence, loss, accidents, emotional neglect. The symptoms are wearing: flashbacks, nightmares, dissociation, constant over-arousal, the sense of being cut off from oneself or from the world.

What may make ketamine particularly relevant here? Traumatic memories are deeply encoded in the nervous system. Classical therapies need time to reach those layers. Ketamine can ease access to emotionally charged content by briefly reducing cognitive control and opening access to inner experience.

First RCT of ketamine in PTSD

Feder and colleagues (2014) published in JAMA Psychiatry the first randomized controlled crossover trial of ketamine in chronic PTSD. Forty-one participants were included. Compared to active placebo (midazolam), a single ketamine infusion showed a significantly greater reduction of PTSD symptoms 24 hours after administration. That was a proof of concept on a very narrow basis, the first indication that ketamine can have any effect in PTSD at all.

Feder A et al. Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial. JAMA Psychiatry. 2014;71(6):681–688.
PTSD meta-analysis 2024

Borgogna and colleagues published a meta-analysis of six RCTs with 221 participants in 2024. They found only a small advantage of ketamine over control conditions (g = 0.27), which was no longer statistically secure after correction for publication bias (g = 0.20; 95% CI from minus 0.08 to 0.48). Against active controls, no difference was found. The authors consider it possible that part of the reported effect goes back to placebo effects, because blinding is hard to maintain with a substance this noticeable. That is a serious objection, and I do not want to leave it out here.

Borgogna NC et al. So how special is ‘special K’? A systematic review and meta-analysis of ketamine for PTSD RCTs. Eur J Psychotraumatol. 2024.
Honest framing, the PTSD evidence is nuanced

An important finding: Abdallah and colleagues tested in 2022, in one of the largest RCTs to date (n = 158 veterans), repeated ketamine infusions in PTSD. They found significant improvements in depression, but no significant effect on the core PTSD symptoms (PCL-5, CAPS-5). That means the evidence for ketamine in PTSD is promising, but not yet consistent. The most favorable courses so far are described in combination with psychotherapy, but large controlled studies on this are still missing.

7. Ketamine can open a door, therapy can turn it into a room

To me, this is one of the most important points. And it is often underestimated.

Ketamine changes consciousness. It opens a window in which new perspectives can arise, in which old patterns are less rigid, in which something stuck becomes movable again. But this window closes.

What you do in that window makes the difference. That is the core of ketamine-assisted psychotherapy.

KAP systematic review 2022

Drozdz and colleagues reviewed seventeen papers with 603 participants on ketamine-assisted psychotherapy in 2022 in the Journal of Pain Research. Their cautious conclusion: under specific circumstances, psychotherapeutic accompaniment before, during, and after the session can prolong the effect, observed above all in pain, anxiety, and depressive symptoms. No direct comparison against ketamine alone was made. Large controlled studies are still missing, and the authors explicitly call for them.

Drozdz SJ et al. Ketamine assisted psychotherapy: a systematic narrative review of the literature. J Pain Res. 2022;15:1691–1706.
Retrospective analysis 2025

Sakopoulos and Todman retrospectively reviewed treatment records of people with treatment-resistant depression who had received ketamine with or without accompanying weekly psychotherapy, published in 2025 in the International Journal of Molecular Sciences. All groups improved, most markedly the group receiving psychotherapy. Because this is a retrospective review without randomization, it can show an association but cannot prove a cause. As a possible explanation the authors describe a window of heightened synaptic malleability after the infusion.

Sakopoulos S, Todman M. The effects of psychotherapy on single and repeated ketamine infusion(s) therapy for TRD. Int J Mol Sci. 2025;26(14):6673.

Ketamine alone is like a door that opens briefly. Without integration, it is easy to walk past it. With accompaniment, it can become a room you can actually step into.

8. What you experience in a session

Every experience is unique. But there are recurring patterns that most people describe.

Dissociation

An observer-like sense, as if you were slightly outside of yourself. Some experience this as liberating. Others experience it as frightening, especially the first time. Both are normal, and both belong to the expected effects.

Old emotions

Things that have not had space for a long time may surface. Sometimes tears. Sometimes anger. Sometimes simply a deep exhaustion that is finally given room.

Inner images

Many describe visual or symbolic experiences. Not hallucinations in the literal sense, more like vivid dreaming with full awareness.

Body sensations

Warmth, tingling, a sense of softness or heaviness. Many experience a deep state of bodily relaxation that feels very unfamiliar.

Many people experience this as both shaking and clarifying. Sometimes something rises that has had no place for years. That can be overwhelming. But this is exactly what a safe therapeutic frame is for: not to push it away, but to say: you are allowed to be here.

Side effects you should know about: a temporary rise in blood pressure and pulse is among the most common acute effects. Added to this are nausea and vomiting, headache, dizziness, blurred vision, anxiety or restlessness during the effect, and psychotomimetic effects, meaning unfamiliar perceptions. These effects usually subside within one to two hours. More rarely, particularly with too rapid administration, apnea and laryngospasm have been described. With repeated use the liver and the bladder can be affected. This is why I stay in the room the entire time, and why heart rate and blood pressure are monitored throughout.

9. Does ketamine cause addiction? An honest answer

I hear this question in every first conversation. And it is justified.

Ketamine is misused recreationally, often in very high doses, daily, combined with other substances. That carries real risks: psychological dependence, bladder damage (so-called ketamine cystitis), and memory problems with chronic use.

But that is a completely different setting from therapeutic use.

Risk assessment, recreational versus medical use

Morgan and Curran summarized the harms of ketamine use in 2012 in Addiction. Their finding is clear: frequent, high-dose use is linked to bladder damage, memory impairment, and dependence, and many regular users report that they wanted to stop and could not. A physical withdrawal syndrome as with alcohol or benzodiazepines is not described for ketamine in the same way. A psychological dependence can nevertheless develop.

Morgan CJA, Curran HV. Ketamine use: a review. Addiction. 2012;107(1):27–38.

In therapeutic use, different parameters apply: precisely dosed single doses with long intervals between them, under medical supervision, with psychological preparation and integration. A physical withdrawal syndrome as with alcohol, benzodiazepines, or opioids is not described for ketamine in the same way. It carries a potential for misuse nonetheless. That is why every application belongs in medical hands.

But: psychological dependence can develop when people use ketamine to escape feelings, without therapeutic accompaniment. The opposite of the therapeutic goal. That is why the frame is decisive. The point is not to create a new attachment. The point is to become freer.

Reframe

Ketamine cystitis is real. It is described above all with daily consumption of high doses over months, a pattern that has nothing to do with a medically dosed infusion given weeks apart. But a residual risk with repeated treatment cannot be ruled out on that basis, because long-term data are missing. That is why I actively ask about bladder symptoms during a series of treatments, and check the urine.

10. Mechanism and clinical practice: what the neurobiology means for the experience

I would like to go one step further. Because the neurobiology can explain something that many patients describe intuitively, but find hard to put into words.

In severe depression and chronic stress there are indications of a reduced density of synaptic connections, above all in the prefrontal cortex, which is responsible for perspective, planning, and emotional regulation. These findings come predominantly from animal models and examinations of brain tissue. In the living human being we cannot currently see this directly.

What ketamine could set in motion is, at its core, a regenerative process. In animal models, new synaptic connections form within hours. This state of heightened neuronal plasticity could be the biological window in which therapeutic work can act more deeply. In humans this is not proven.

Many people describe after a session that their head had become quieter and that they could feel something again.

How much of this goes back to the neurobiological effect and how much to expectation, attention, and setting cannot honestly be separated. Probably both act together. That does not make the experience any less valuable.

11. How a treatment with me unfolds

Every person brings their own story, a different nervous system, and an individual body. That is why no treatment with me starts with an infusion. It starts with real listening.

Step 1: history and integrative diagnostics

We begin with an in-depth conversation about your life, your symptoms, previous therapies, and inner themes. This also includes physical diagnostics, because emotional state and biochemical foundations can be closely connected.

What I look at

  • Nutrients: vitamin D, B12, omega-3, magnesium, zinc
  • Hormones and thyroid: including fT3, fT4, anti-TPO
  • Gut flora and inflammation markers: hsCRP, microbiome status
  • Stress system: cortisol day profile, HRV, sleep profile
  • Environmental toxins: when history points to it (mold, heavy metals)
  • Cardiovascular: particularly relevant before ketamine (blood-pressure monitoring)

Step 2: preparation and setting conversation

Before you receive ketamine, we clarify: what is your goal? What is allowed to come up? What do you need if it gets intense? This conversation is decisive. It gives your experience a safe frame.

Step 3: the infusion, precisely dosed, medically monitored

The dose is calculated by body weight and lies far below an anesthetic dose. I set the exact dose individually. The infusion runs slowly over about forty minutes, with continuous monitoring of heart rate and blood pressure. Eye protection reduces external stimuli. Music carries the process emotionally. I am present the entire time.

The setting makes the difference. Ketamine can do more when the room around it is shaped properly.

What you have to plan for on the treatment day: please come fasting, I will discuss the exact times with you beforehand, otherwise there is a risk of aspiration. After the infusion you stay in the practice until you are safely oriented. On the day of treatment you must not drive a vehicle or operate machinery, and that applies for at least 24 hours. Please arrange for someone to accompany you home. Alcohol and cannabis are off the table that day. Tell me beforehand which medications you take. Benzodiazepines, sympathomimetics, and theophylline, among others, can alter the effect, and benzodiazepines may weaken the antidepressant effect.

Step 4: integration

After every session we talk: what did you experience? Which feelings were there? What has shifted? The experience is the impulse. Integration turns it into change.

Step 5: course and closure

How many sessions make sense is something we decide together as we go. Some people describe more clarity afterwards, more access to feelings, more self-leadership. Those are individual courses from my practice, not a success rate. My goal is not for you to stay with me. My goal is that you learn to accompany yourself.

12. Why I always work integratively

Many people, when they think of mental health, think only of conversations, diagnoses, and medications. But what about a vitamin D deficiency that can impair drive and mood? About chronic inflammation that weighs on body and nervous system? About a dysbiosis in the gut that could influence emotional experience via the gut-brain axis?

Your emotional state can have biochemical foundations. Ketamine does not treat isolated symptoms. It is part of an integrative approach that takes all levels into account.

Reframe: ketamine is not a shortcut

Ketamine does not replace diagnostic work, sleep, the shaping of relationships, or a foundation built from nutrition and movement. It is a tool within a systemic approach. Anyone who treats ketamine as a shortcut misses the decisive point: a window that ketamine can open is only fully usable when the rest of the system is also at work.

13. Who ketamine is suited for, and who it is not

Possibly suitable Treatment-resistant depression (at least 2 antidepressants without sufficient effect). PTSD, where classical therapies have not been enough. Bipolar depression in psychiatric supervision and with a mood stabilizer. Whether a treatment is justifiable in an individual case is decided only after a medical examination and only where there is a clear medical indication.
Contraindications / not yet suitable Untreated or active psychosis. Active mania. Uncontrolled high blood pressure, severe cardiac disease, known aneurysm. Raised intracranial pressure. Glaucoma. Untreated hyperthyroidism. Severe liver disease. Kidney disease or existing bladder complaints. Active substance-use disorder without accompanying treatment. Pregnancy and breastfeeding. Children and adolescents, because reliable data are lacking. A lack of willingness to prepare and integrate.
Regulatory note: esketamine as a nasal spray has been authorized in the EU since December 2019 for treatment-resistant depression, and since February 2021 also for acute depressive episodes with psychiatric emergency character, and it is administered under supervision in a medical facility. Intravenous racemic ketamine remains off-label for psychiatric indications in Germany, that is, it is used without a formal authorization for this purpose, under the individual responsibility of the physician. The German treatment guideline so far issues no recommendation for it. This is permissible, but it requires a careful case-by-case assessment, thorough information, and your explicit consent. Statutory health insurance does not cover the cost, this is a purely self-pay service.

What if there is no severe diagnosis?

If you have read this far, you have learned a lot about treatment-resistant depression, PTSD, and bipolar disorder. That is the scientific language in which ketamine is researched and described. Studies so far exist only for people with a diagnosis.

In my practice I also see people without a severe diagnosis who cannot move forward through thinking alone. Whether a ketamine-assisted treatment is justifiable in an individual case is decided only after a medical examination and only where there is a clear medical indication. Without an indication I do not prescribe ketamine.

My position, and its limit

I consider experiencing an underrated part of change. But ketamine is not an offer for expanding consciousness, it is a prescription medication with real risks. It only comes into question where there is a clear medical indication, after examination, information, and a case-by-case assessment.

We live in a culture that places cognitive understanding above bodily experience. We analyze, name, categorize. We know a lot about ourselves. And still little often changes. Not because we know too little, but because knowing alone is often not enough. For some people the key may lie more in experiencing than in understanding.

Ketamine can temporarily make the analytical part of the mind, the part that constantly judges, controls, and comments, quieter. What remains is a deeper access to what is actually going on inside us. Images, feelings, connections that do not appear in normal waking consciousness. That is not a mystical process. The mechanism under discussion is a neurobiological one: fewer filters, more access.

What is observation and what is evidence

What I see in my practice are individual courses. They do not replace a study and say nothing about what would happen for you. I describe them here as observation, not as evidence.

So please do not let the clinical language in this article put you off. If you have the feeling that pure thinking is reaching its limits, a conversation is the right first step. Whether that leads to a ketamine-assisted treatment is not decided by it. That depends on the examination, the diagnosis, and a careful assessment, and in many cases a different path is the better one.

14. Self-check: could ketamine be relevant for you?

Block 1: your treatment history

  • Have you tried at least two different antidepressants in adequate dose and duration without significant improvement?
  • Are you in psychotherapy, or have you been, and notice that you are “going in circles” or not really getting through?
  • Do you have the feeling that you know what your problem is, but cannot find emotional access to it?
  • Do you have a diagnosis of PTSD, and have classical trauma therapies so far helped only a little?

Block 2: your inner readiness

  • Are you willing to let yourself enter a deeper, possibly intense inner experience?
  • Can you imagine working seriously with what comes up after a session?
  • Do you have a basic interest in what is going on inside you, beyond the symptom?
  • Are you not actively at risk of substance dependence or in an acute psychotic phase?

Please seek prompt medical care for:

  • Acute suicidality. Ketamine is not a substitute for acute care. Please call the emergency number 112 immediately, or Telefonseelsorge 0800 111 0 111
  • An unclear diagnosis. Before ketamine is considered, the underlying diagnosis must be in place
  • Known cardiac disease or uncontrolled high blood pressure
  • Active psychosis or known schizophrenia
  • Pregnancy, plans for pregnancy, or breastfeeding

Ketamine within the system, the connection to my other specialty areas

Mental health is rarely isolated. Associations are discussed between mood and physical factors such as inflammation, the gut microbiome, mold toxins, or a heavy-metal load. Reliable studies combining these topics with a ketamine treatment do not exist so far. I look at these levels because they can play a role in an individual case, not because an association has been proven.

Ketamine

Neuroplasticity, therapeutic window, integration

this area
Gut Reset

Most of the body’s serotonin is produced in the gut. Whether that influences mood is open, because this serotonin does not reach the brain.

Mold

Associations between mycotoxins, inflammation, and the nervous system are discussed. Evidence for an influence on a ketamine treatment is lacking.

Heavy metals

Mercury and lead can affect enzymes in nerve metabolism. An effect on the course of a ketamine treatment is not established by this.

Important note: this article is general information and does not replace a medical examination, a diagnosis, or individual advice. Ketamine is a prescription medication. Any use outside medical supervision is dangerous and can be life-threatening, and intravenous self-administration without monitoring all the more so. Please do not stop an ongoing medication on your own, speak with the doctor who prescribed it. In an acute crisis in Germany: emergency number 112, medical on-call service 116 117, Telefonseelsorge 0800 111 0 111.

Sources

  1. Krystal JH, Kavalali ET, Monteggia LM. Ketamine and rapid antidepressant action: new treatments and novel synaptic signaling mechanisms. Neuropsychopharmacology. 2024;49(1):41–50. DOI: 10.1038/s41386-023-01629-w
  2. Li N, Lee B, Liu RJ et al. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science. 2010;329(5994):959–964. DOI: 10.1126/science.1190287
  3. Rodolico A et al. Efficacy and safety of ketamine and esketamine for unipolar and bipolar depression: an overview of systematic reviews with meta-analysis. Front Psychiatry. 2024;15:1325399. DOI: 10.3389/fpsyt.2024.1325399
  4. Alnefeesi Y et al. Real-world effectiveness of ketamine in treatment-resistant depression: a systematic review & meta-analysis. J Psychiatr Res. 2022;151:693–709.
  5. Nikolin S et al. Ketamine for the treatment of major depression: a systematic review and meta-analysis. eClinicalMedicine. 2023.
  6. Shiroma PR et al. A randomized, double-blind, active placebo-controlled study of efficacy, safety, and durability of repeated vs single subanesthetic ketamine for treatment-resistant depression. Transl Psychiatry. 2020;10:206. DOI: 10.1038/s41398-020-00897-0
  7. Bahji A, Zarate CA, Vazquez GH. Ketamine for bipolar depression: a systematic review. Int J Neuropsychopharmacol. 2021;24(7):535–541. DOI: 10.1093/ijnp/pyab023
  8. Feder A et al. Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial. JAMA Psychiatry. 2014;71(6):681–688. DOI: 10.1001/jamapsychiatry.2014.62
  9. Feder A et al. A randomized controlled trial of repeated ketamine administration for chronic posttraumatic stress disorder. Am J Psychiatry. 2021;178(2):193–202. DOI: 10.1176/appi.ajp.2020.20050596
  10. Abdallah CG et al. Dose-related effects of ketamine for antidepressant-resistant symptoms of PTSD in veterans. Neuropsychopharmacology. 2022;47(8):1574–1581.
  11. Borgogna NC et al. So how special is ‘special K’? A systematic review and meta-analysis of ketamine for PTSD RCTs. Eur J Psychotraumatol. 2024.
  12. Almeida K et al. Effectiveness of ketamine for the treatment of PTSD in real world settings. 2024.
  13. Drozdz SJ et al. Ketamine assisted psychotherapy: a systematic narrative review of the literature. J Pain Res. 2022;15:1691–1706. DOI: 10.2147/JPR.S360733
  14. Sakopoulos S, Todman M. The effects of psychotherapy on single and repeated ketamine infusion(s) therapy for TRD. Int J Mol Sci. 2025;26(14):6673. DOI: 10.3390/ijms26146673
  15. Morgan CJA, Curran HV. Ketamine use: a review. Addiction. 2012;107(1):27–38. DOI: 10.1111/j.1360-0443.2011.03576.x
  16. Schak KM et al. Potential risks of poorly monitored ketamine use in depression treatment. Am J Psychiatry. 2016;173(3):215–218.
  17. Singh JB et al. Approval of esketamine for treatment-resistant depression. Lancet Psychiatry. 2020;7(3):232–235. DOI: 10.1016/S2215-0366(19)30533-4
  18. EMA. Spravato (esketamine): EU marketing authorisation December 2019, extended February 2021. European Medicines Agency.
  19. Anand A et al. Ketamine versus ECT for nonpsychotic treatment-resistant major depression. N Engl J Med. 2023;388(25):2315–2325. DOI: 10.1056/NEJMoa2302399
  20. Guo X et al. Comparative safety and tolerability of ketamine for treatment-resistant depression: a meta-analysis. Front Pharmacol. 2025. DOI: 10.3389/fphar.2025.1681060

Have questions or want to book an appointment?

We'd be happy to advise you personally at our practice.

Book appointment